Crowe’s pediatric immune response research lauded

Bill Snyder
February 23, 2017

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017-2018 recipient of the Samuel Rosenthal Prize for Excellence in Academic Pediatrics. The $50,000 prize from the Leighton A. Rosenthal Family Foundation and the Milton A. and Charlotte R. Kramer Charitable Foundation, both in Cleveland, Ohio, will be awarded over two years to Vanderbilt University Medical Center (VUMC) to pay direct costs for Crowe’s research and education activities.

Team isolates new antibodies that may aid RSV vaccine design

Bill Synder
February 15, 2017

Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide. Reporting this week in the journal Nature Microbiology, James Crowe Jr., M.D., and colleagues describe the isolation of 13 new human monoclonal antibodies that recognize a conformation of RSV’s fusion (F) protein, which fuses the viral particle to its target cell in the lung.

Introducing Vanderbilt’s Program for Next Generation Vaccines – Integrating Structural Biology with Big Data

Heather Darling
February 13, 2017

This program builds on an existing collaboration between PIs Jens Meiler (VU) and James Crowe (VUMC) but transforms it substantially, expands scope, and shifts focus to the next frontier: the integration of big data and structural biology into vaccine design. It adds a comprehensive training program, eight mostly early/mid-career faculty, and a series innovative technologies to form the Vanderbilt Program for Next Generation Vaccines.

Six from Vanderbilt to speak at TEDxNashville March 17–18

January 26, 2017

Astrophysicists, artists, celebrity chefs and clinical psychologists will be among the speakers at the eighth annual TEDxNashville. The two-day event, which will be held March 17-18 at the Tennessee Performing Arts Center’s Andrew Jackson Hall, celebrates community building and “ideas worth spreading.” The list of speakers includes the following from Vanderbilt: Julie Adams, professor of computer science and computer engineering; James Crowe Jr., Ann Scott Carell Professor of Pathology, Microbiology and Immunology and director of the Vanderbilt Vaccine Center;

VVC Holiday Toy Drive

December 21, 2016

The Vanderbilt Vaccine Center staff and faculty donated over 60 gifts to the VUMC Children’s Hospital today! Happy Holidays!

Treatment protects mice from Zika during pregnancy: U.S. study

Julie Steenhuysen
November 7, 2016

A new study of the Zika virus in mice raises hope for a way to protect pregnant women and their babies from the possible repercussions of being infected, U.S. researchers said on Monday. The experimental treatment is derived from antibodies taken from the blood of people who have recovered from Zika infections. Tested on pregnant mice, the treatment reduced levels of the virus in the mothers, and also protected their pups from the ravages of the virus.

Preparing for a return of pox

Bill Snyder
October 24, 2016

Smallpox killed upwards of 500 million people in the 20th century before the virus was eradicated from the earth by large-scale vaccination campaigns. Close relatives in the poxvirus family, including cowpox and monkeypox, are less virulent in humans. But that doesn’t mean smallpox will never return, or that poxvirus infections will not become a greater concern as the number of immunocompromised individuals treated for disorders such as cancer continues to grow.

Research sheds light on how RSV wards off potential vaccines

Bill Snyder
October 24, 2016

Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it. Now a team of scientists at Vanderbilt University Medical Center (VUMC), with colleagues in California and Pennsylvania, believe they know why the virus has been so difficult to neutralize.